Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer
Jalees Rehman(Illinois College), Stephen L. Archer(Queen's University), Péter T. Tóth(University of Chicago), Glenn Marsboom(Johnson & Johnson (United States)), Yanmin Zhang(First Affiliated Hospital of Xi'an Jiaotong University), Hannah J. Zhang(University of Chicago), Aliya N. Husain(University of Chicago), Ravi Salgia(City Of Hope National Medical Center), Zhigang Hong(University of Chicago), Christian Wietholt(University of Chicago)
Cited by 606
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Pediatric Pulmonary Hypertension
|Circulation|2015|1.1k